Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Jerusalem Region, Israel Clinical Trials

A listing of Jerusalem Region, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (237) clinical trials

CINC424A2X01B Rollover Protocol

This roll-over protocol allows patients who are still receiving clinical benefit to continue to be treated from multiple protocols in one program spanning multiple indications during the completion of the parent study/(ies). The population for the roll-over study should be consistent with the population defined in the program parent study/(ies). ...

Phase

0.0 miles

Learn More »

Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

The goal of the present study is to evaluate the effect of D-serine, added to antipsychotic treatment, on negative and cognitive symptoms in schizophrenia. The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.

Phase

0.0 miles

Learn More »

Comparison of Coronary CT Angiography to Invasive Coronary Angiography

40 Patients who are scheduled to undergo coronary angiogram will be recruited at Mount Scopus and Ein Kerem. Patients will be excluded if they have one or more of the following conditions 1. CABG or stent implantation in the past. 2. Atrial fibrillation 3. Contraindication for beta blockers 1. Obstructive ...

Phase N/A

0.0 miles

Learn More »

Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors

The present protocol is designed to investigate the potential application of allogeneic cell-mediated immunotherapy in metastatic solid tumors similarly to the well established graft versus leukemia (GVL) effects in patients with hematologic malignancies. Patients with metastatic solid tumors resistant to conventional modalities will be eligible to participate in a treatment ...

Phase

0.0 miles

Learn More »

Non-Polymer-Based Rapamycin-Eluting Stents to Prevent Restenosis

In-stent restenosis remains the major problem limiting the efficacy of coronary stenting. Either sirolimus or paclitaxel drug-eluting stents have been demonstrated to decrease neointima proliferation resulting in a remarkable reduction of restenosis rate. However, despite the outstanding results achieved with this novel approach to restenosis, some caveats still remain. Although ...

Phase

0.0 miles

Learn More »

Genetic Determinants of the Response to Salbutamol Among Asthma Patients

The response to salbutamol varies greatly among individuals. Data from previous studies indicate that some of the variability is accounted for by genetic polymorphisms in the gene encoding for the adrenoceptor subtype β2. The current study was designed to evaluate variability in the response to salbutamol among recently diagnosed patients ...

Phase N/A

0.0 miles

Learn More »

Relationship Between Folic Acid and Warfarin Metabolism and Effect

Folic acid supplementation has been shown previously to be associated with enhanced formation of p-HPPH from phenytoin, a metabolic pathway which is predominantly mediated through the activity of CYP2C9. The metabolism of S warfarin, the more active enantiomer of warfarin, is also mediated predominantly through the activity of CYP2C9. The ...

Phase N/A

0.0 miles

Learn More »

Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo

The role played by ß2AR polymorphisms in determining the bronchial response to ß2AR agonist drugs, has been confirmed by several studies. The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and drug responsiveness. An ex-vivo model (organ bath ...

Phase N/A

0.0 miles

Learn More »

Genetic Determinants of Warfarin Anticoagulation Effect

The response to warfarin varies greatly among individuals. Some of this variability can be ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the metabolism of S warfarin. In addition genetic polymorphism in other genes (i.e. VKORC1, factor VII) have been shown to account for some ...

Phase N/A

0.0 miles

Learn More »

Evaluation of CYP2C9 Activity

The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity To correlate phenytoin ...

Phase N/A

0.0 miles

Learn More »